{"url_path":"/sec/cntb/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1835268/0001835268-26-000020-index.html","accession_number":"0001835268-26-000020","cik":"0001835268","ticker":"CNTB","issuer_name":"Connect Biopharma Holdings Ltd","edgar_url":"https://www.sec.gov/Archives/edgar/data/1835268/0001835268-26-000020-index.html","primary_entity_key":"0001835268","primary_entity_name":"Connect Biopharma Holdings Ltd"},"word_count":57,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\n(c) Trading Plans\n\nDuring the quarter ended March 31, 2026, none of our directors or Section 16 officers adopted or terminated a (i) Rule 10b5-1 trading arrangement (as defined in Item 408(a) of Regulation S-K) or (ii) non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).\n\n25\n\n[TABLE OF CONTENTS](#i46b71458e1224d37a858ff5acc38daea_7)"}